Document Detail


Personalized medicine: reality and reality checks.
MedLine Citation:
PMID:  19417116     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The evolving era of pharmacogenomics and personalized medicine is greeted with optimism by many, but this sentiment is not universally shared. The existence of diametrically opposed opinions concerning the potential benefits and obstacles facing the widespread implementation of genomic medicine should stimulate discussion and guide the design of studies to establish the value of interventions targeted at the level of individual patients. One of the more controversial aspects of personalized medicine is whether the anticipated benefits will be realized at an acceptable cost. Recently released analyses suggest that the returns on investment depend on the particular scenario and are different for different stakeholders. On the other hand, cost is only one of the challenges regarding implementation of personalized medicine. Among these are the development of universal standards for managing genomic information in electronic medical records, improvement in the collection and interpretation of clinical phenotype data, and new strategies to educate practitioners and patients/consumers. The reality is that personalized medicine is upon us; open discourse and periodic reality checks will be necessary as we confront it.
Authors:
J Steven Leeder; Stephen P Spielberg
Related Documents :
9893856 - Dichromacy characterized by chrominance planes.
20681096 - Reversing the gaze: constructing european race discourse as modern witchcraft practice.
17505496 - Personalized medicine: elusive dream or imminent reality?
16121326 - An anatomical study of the pterygoalar bar and the pterygoalar foramen.
8139876 - Diagnosis and management of croup and epiglottitis.
23125296 - A staged management of prolonged chylothorax in a patient with yellow nail syndrome.
Publication Detail:
Type:  Comment; Journal Article    
Journal Detail:
Title:  The Annals of pharmacotherapy     Volume:  43     ISSN:  1542-6270     ISO Abbreviation:  Ann Pharmacother     Publication Date:  2009 May 
Date Detail:
Created Date:  2009-05-06     Completed Date:  2009-07-15     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9203131     Medline TA:  Ann Pharmacother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  963-6     Citation Subset:  IM    
Affiliation:
Division of Clinical Pharmacology and MedicalToxicology, Children's Mercy Hospitals and Clinics, 2401 Gillham Rd., Kansas City, MO 64108, USA. sleeder@cmh.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Drug Costs*
Economics, Pharmaceutical
Genomics
Health Care Costs*
Humans
Pharmacogenetics*
Comments/Corrections
Comment On:
Ann Pharmacother. 2009 May;43(5):958-62   [PMID:  19417115 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Personalized medicine: boon or budget-buster?
Next Document:  Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiolog...